For more than a decade, our team of cell biologists, engineers, and surgeons have worked to harness the potential of adipose-derived adult regenerative cells to repair or restore lost or damaged tissues and organs. Cytori has sought out world class partners and other relationships to expand and globally commercialize its cell therapy in the cardiovascular, soft tissue, cell banking, and research markets.

Lorem Vascular: License to Cardiovascular, Renal & Diabetes Markets in Asia-Pacific

In October 2013, Cytori announced a partnership with Lorem Vascular to commercialize Cytori Cell Therapy for the cardiovascular, renal and diabetes markets as well as all other indications, excepting hair and aesthetics, in China, Hong Kong, Malaysia, Singapore and Australia. Lorem Vascular intends to initiate an immediate launch in Hong Kong, Singapore and Australia, and a subsequent launch into China and Malaysia, pending regulatory approvals. >>More

Biomedical Advanced Research and Development Authority (BARDA): Contract to Develop Cell Therapy for Thermal Burns

In September 2012, Cytori announced that it had been awarded a contract with the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA) to develop cell therapy for thermal burns combined with radiation injury. >>More

Astellas Pharma Inc.: Strategic Equity Agreement

In December 2010, Cytori  entered into a strategic equity agreement with Astellas Pharma to evaluate the potential of adipose derived stem and regenerative cells for the treatment of serious illnesses for which there is no fundamental treatment. Per this agreement, Cytori and Astellas will further explore a collaboration for an advanced regenerative drug technology. >>More

Green Hospital Supply: StemSource® Cell Bank Commercialization in Several Asian Countries

In August 2007, Cytori entered into an exclusive partnership with Green Hospital Supply to commercialize Cytori’s StemSource® 900 series Cell Bank in Japan. The agreement was expanded in June 2008 to include Korea, Taiwan and Thailand. >>More

Bookmark and Share

Cytori is actively pursuing partnerships and collaboration opportunities to advance the Company’s adipose regenerative cell therapies.

To inquire, please contact:

Cytori Therapeutics, Inc.
Business Development Department
Tel: +1.858.458.0900